What is it about?
While randomized controlled trials are considered the gold standard in clinical research, a crucial limitation is their lack of generalizability, partly due to strict eligibility criteria. With the ongoing opioid epidemic, this seems particularly true for regional anesthesia-related randomized controlled trials because preoperative opioid use is a commonly applied exclusion criterion. In this article, we will review the following: (1) the problems associated with restricting randomized controlled trials to opioid-naive populations and (2) possible solutions to improve recruitment and external validity
Featured Image
Photo by freestocks.org on Unsplash
Why is it important?
The recent designation of the opioid epidemic as a national public health emergency emphasizes its national health implications while also recognizing the challenges in research ahead. We highlight the problems and potential solutions to incorporating the opioid-tolerant population into regional anesthesia-related randomized controlled trials. Improving generalizability of study results to the opioid-tolerant cohort will assist clinicians in developing an evidence-based pain management approach for this difficult-to-treat population.
Read the Original
This page is a summary of: To Include or Exclude? That Is the Question for Clinical Researchers Investigating in the Current Opioid Epidemic, Anesthesia & Analgesia, March 2019, Wolters Kluwer Health,
DOI: 10.1213/ane.0000000000004090.
You can read the full text:
Contributors
The following have contributed to this page
